Humoral Immune Responses and Protective Efficacy of Sequential B- and T-cell Epitopes of V Antigen of Yersinia Pestis by Intranasal Immunization in Microparticles

Overview

Journal Med Microbiol Immunol

Specialty Allergy & Immunology

Date 2009 Sep 26

PMID 19779739

Citations 4

Authors

Jayaprakash Babu Uppada

Arif Azam Khan

Ajaz Ahmad Bhat

Ranjana Deshmukh

Donthamsetty Nageswara Rao

Affiliations

Soon will be listed here.

Abstract

Capsular F1 and secretory V antigen are the putative vaccine candidates for plague, caused by Yersinia pestis. Contemplating this, we studied the immunogenicity and protective efficacy of collinearly synthesized B- and T-cell epitopes (B-T constructs) of V antigen entrapped in poly (DL-lactide-co-glycolide) microparticles immunized intranasally using single dose immunization schedule in outbred, H-2(b) and H-2(d) mice. High antibody levels were observed in terms of IgG, IgA and SIgA peak titers in sera and mucosal washes to different B-T constructs. The constructs ai, bi and fi especially showed high peak antibody titers ranging from 51,200 to 204,000, which were maintained till day 120 post immunization. IgG/IgA Specific activity in sera and washes correlated well with the peak antibody titers. Moreover, all the B-T constructs showed mixed IgG1 and IgG2a/2b response, variable immunoreactivity as well as memory response with V antigen. B-T constructs, viz ai, ak, bi, fi, di and ik showed comparatively high isotype levels. These constructs showed high immunoreactivity, and good recall response with V antigen. Finally, in vivo protective study in BALB/c mice demonstrated the protective efficacy of three B-T constructs (ai, bi and fi) against lethal doses of Yersinia pestis till day 20 post challenge, while construct 'id' showed partial protection.

Citing Articles

Polymorphism in the LcrV Antigen Enables Immune Escape From the Protection Conferred by an LcrV-Secreting in a Pseudotuberculosis Mouse Model.

Daniel C, Dewitte A, Poiret S, Marceau M, Simonet M, Marceau L Front Immunol. 2019; 10:1830.

PMID: 31428104 PMC: 6688116. DOI: 10.3389/fimmu.2019.01830.

Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens.

Fan Y, Moon J Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016; 9(1).

PMID: 27038091 PMC: 5045734. DOI: 10.1002/wnan.1403.

Recent publications in medical microbiology and immunology: a retrospective.

Doerr H, Cinatl J Med Microbiol Immunol. 2011; 201(1):1-5.

PMID: 22033658 DOI: 10.1007/s00430-011-0219-9.

Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases.

Ulery B, Kumar D, Ramer-Tait A, Metzger D, Wannemuehler M, Narasimhan B PLoS One. 2011; 6(3):e17642.

PMID: 21408610 PMC: 3048296. DOI: 10.1371/journal.pone.0017642.

References

Hodge L, Simecka J . Role of upper and lower respiratory tract immunity in resistance to Mycoplasma respiratory disease. J Infect Dis. 2002; 186(2):290-4. DOI: 10.1086/341280. View

Philipovskiy A, Cowan C, Wulff-Strobel C, Burnett S, Kerschen E, Cohen D . Antibody against V antigen prevents Yop-dependent growth of Yersinia pestis. Infect Immun. 2005; 73(3):1532-42. PMC: 1064938. DOI: 10.1128/IAI.73.3.1532-1542.2005. View

Robert-Guroff M . IgG surfaces as an important component in mucosal protection. Nat Med. 2000; 6(2):129-30. DOI: 10.1038/72206. View

Tripathi V, Chitralekha K, Bakshi A, Tomar D, Deshmukh R, Baig M . Inducing systemic and mucosal immune responses to B-T construct of F1 antigen of Yersinia pestis in microsphere delivery. Vaccine. 2006; 24(16):3279-89. DOI: 10.1016/j.vaccine.2006.01.031. View

Cornelis G . Yersinia type III secretion: send in the effectors. J Cell Biol. 2002; 158(3):401-8. PMC: 2173816. DOI: 10.1083/jcb.200205077. View

Nedialkov Y, Motin V, Brubaker R . Resistance to lipopolysaccharide mediated by the Yersinia pestis V antigen-polyhistidine fusion peptide: amplification of interleukin-10. Infect Immun. 1997; 65(4):1196-203. PMC: 175117. DOI: 10.1128/iai.65.4.1196-1203.1997. View

Blisnick T, Ave P, Huerre M, Carniel E, Demeure C . Oral vaccination against bubonic plague using a live avirulent Yersinia pseudotuberculosis strain. Infect Immun. 2008; 76(8):3808-16. PMC: 2493205. DOI: 10.1128/IAI.00034-08. View

Maggi E, Parronchi P, Manetti R, Simonelli C, Piccinni M, Rugiu F . Reciprocal regulatory effects of IFN-gamma and IL-4 on the in vitro development of human Th1 and Th2 clones. J Immunol. 1992; 148(7):2142-7. View

Hill J, Leary S, Griffin K, Williamson E, Titball R . Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization. Infect Immun. 1997; 65(11):4476-82. PMC: 175643. DOI: 10.1128/iai.65.11.4476-4482.1997. View

10.

Ahmed R, Gray D . Immunological memory and protective immunity: understanding their relation. Science. 1996; 272(5258):54-60. DOI: 10.1126/science.272.5258.54. View

11.

Croft M, Swain S . B cell response to T helper cell subsets. II. Both the stage of T cell differentiation and the cytokines secreted determine the extent and nature of helper activity. J Immunol. 1991; 147(11):3679-89. View

12.

Holmgren J, Czerkinsky C . Mucosal immunity and vaccines. Nat Med. 2005; 11(4 Suppl):S45-53. DOI: 10.1038/nm1213. View

13.

Jemmerson R, Blankenfeld R . Affinity consideration in the design of synthetic vaccines intended to elicit antibodies. Mol Immunol. 1989; 26(3):301-7. DOI: 10.1016/0161-5890(89)90084-9. View

14.

Williamson E, Vesey P, Gillhespy K, Eley S, Green M, Titball R . An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model. Clin Exp Immunol. 1999; 116(1):107-14. PMC: 1905224. DOI: 10.1046/j.1365-2249.1999.00859.x. View

15.

Williamson E, Eley S, Stagg A, Green M, Russell P, Titball R . A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague. Vaccine. 1997; 15(10):1079-84. DOI: 10.1016/s0264-410x(96)00303-9. View

16.

Sabhnani L, Manocha M, Sridevi K, Shashikiran D, Rayanade R, Rao D . Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles. FEMS Immunol Med Microbiol. 2003; 38(3):215-29. DOI: 10.1016/S0928-8244(03)00170-6. View

17.

Yamanaka H, Hoyt T, Yang X, Golden S, Bosio C, Crist K . A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague. Infect Immun. 2008; 76(10):4564-73. PMC: 2546814. DOI: 10.1128/IAI.00581-08. View

18.

Williamson E, Eley S, Stagg A, Green M, Russell P, Titball R . A single dose sub-unit vaccine protects against pneumonic plague. Vaccine. 2000; 19(4-5):566-71. DOI: 10.1016/s0264-410x(00)00159-6. View

19.

Jiao X, Hirano T, Hou Y, Gu X . Specific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosaccharide conjugate vaccine. Infect Immun. 2002; 70(11):5982-9. PMC: 130355. DOI: 10.1128/IAI.70.11.5982-5989.2002. View

20.

Cornelius C, Quenee L, Overheim K, Koster F, Brasel T, Elli D . Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague. Infect Immun. 2008; 76(12):5588-97. PMC: 2583586. DOI: 10.1128/IAI.00699-08. View